Search

Your search keyword '"Davendra Sohal"' showing total 240 results

Search Constraints

Start Over You searched for: Author "Davendra Sohal" Remove constraint Author: "Davendra Sohal"
240 results on '"Davendra Sohal"'

Search Results

1. Disparities in Clinical Trial Participation: A Cross-Sectional Survey of Cancer Patients at a Midwest Academic Medical Center

2. Role of CD47 gene expression in colorectal cancer: a comprehensive molecular profiling study

Catalog

Books, media, physical & digital resources

4. COVID‐19 pandemic and impact on cancer clinical trials: An academic medical center perspective

5. Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts

6. Correction: Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis.

7. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis.

8. Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration.

10. Radiation therapy in borderline resectable pancreatic cancer: A review

12. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

16. Figure S1 from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer

17. Supplemental Tables S1-S3 from Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative

18. Supp tables 1-5 from Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation

19. Supplementary Methods from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer

20. Supp Methods from Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation

21. Data from Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation

22. Supplementary Figure from Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma

23. Data from Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative

24. Data from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer

25. Supplementary Tables from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer

26. Supplemental Material from Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative

27. Supp Figs 1-5 from Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation

28. Data from Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma

29. Supplementary Table from Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma

30. Supplementary Figures 1-4 from Methylome Profiling Reveals Distinct Alterations in Phenotypic and Mutational Subgroups of Myeloproliferative Neoplasms

31. Supplementary Tables 1-7 from Methylome Profiling Reveals Distinct Alterations in Phenotypic and Mutational Subgroups of Myeloproliferative Neoplasms

33. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline

35. Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer

36. A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours

37. Surgical Outcome Results From SWOG S1505

38. Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study

39. Primer on Hereditary Cancer Predisposition Genes Included Within Somatic Next-Generation Sequencing Panels

40. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program

41. Analysis of HLA gene expression in patients with dMMR/MSI-H colorectal carcinoma resistant to immune checkpoint inhibitors

42. Impact of patient characteristics and treatment patterns on outcomes in potentially resectable pancreatic cancer (PC)

43. Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant

44. An adaptive approach to neoadjuvant therapy to maximize resection rates for pancreatic adenocarcinoma: A phase II trial

45. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

46. Is There a Benefit to Adjuvant Chemotherapy in Resected, Early Stage Pancreatic Ductal Adenocarcinoma?

47. Clinical Predictors of Locally Advanced Pathology in Esophageal Adenocarcinoma

50. Systemic Therapy for Resected Pancreatic Adenocarcinoma: How Much is Enough?